0001493152-22-021233.txt : 20220804 0001493152-22-021233.hdr.sgml : 20220804 20220804070539 ACCESSION NUMBER: 0001493152-22-021233 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220804 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220804 DATE AS OF CHANGE: 20220804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Xtant Medical Holdings, Inc. CENTRAL INDEX KEY: 0001453593 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 205313323 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34951 FILM NUMBER: 221134605 BUSINESS ADDRESS: STREET 1: 664 CRUISER LANE CITY: BELGRADE STATE: MT ZIP: 59714 BUSINESS PHONE: 406-388-0480 MAIL ADDRESS: STREET 1: 664 CRUISER LANE CITY: BELGRADE STATE: MT ZIP: 59714 FORMER COMPANY: FORMER CONFORMED NAME: Bacterin International Holdings, Inc. DATE OF NAME CHANGE: 20100615 FORMER COMPANY: FORMER CONFORMED NAME: K KITZ INC DATE OF NAME CHANGE: 20090108 8-K 1 form8-k.htm
0001453593 false 0001453593 2022-08-04 2022-08-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

 

 

Date of Report (Date of earliest event reported): August 4, 2022

 

 

 

XTANT MEDICAL HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-34951   20-5313323

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

664 Cruiser Lane

Belgrade, Montana

   59714
(Address of principal executive offices)   (Zip Code)

 

(406) 388-0480

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.000001 per share   XTNT   NYSE American LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 4, 2022, Xtant Medical Holdings, Inc. (the “Company”) announced its financial results for the three and six months ended June 30, 2022. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information in Item 2.02 of this report (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing.

 

To supplement its consolidated financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”), the Company uses certain non-GAAP financial measures, such as non-GAAP adjusted EBITDA, which are included in the press release furnished as Exhibit 99.1 to this report. The Company’s non-GAAP adjusted EBITDA is calculated by adding back to net loss the charges for other expense, depreciation and amortization expense, interest expense, and tax expense and further adjusted by adding back in or excluding, as appropriate, non-cash compensation, separation related expenses, and litigation reserve.

 

The Company uses adjusted EBITDA and the other non-GAAP measures in making operating decisions because it believes these measures provide meaningful supplemental information regarding its core operational performance. Additionally, these measures give the Company a better understanding of how it should invest in sales and marketing and research and development activities and how it should allocate resources to both ongoing and prospective business initiatives. The Company also uses these measures to help make budgeting and spending decisions, for example, among sales and marketing expenses, general and administrative expenses, and research and development expenses. Additionally, the Company believes its use of non-GAAP adjusted EBITDA and other non-GAAP measures facilitates management’s internal comparisons to historical operating results by factoring out potential differences caused by charges not related to its regular, ongoing business, including, without limitation, non-cash charges and certain large and unpredictable charges.

 

As described above, the Company excludes the following items from its non-GAAP financial measures for the following reasons:

 

Non-cash compensation. The Company excludes non-cash compensation, which is a non-cash charge related to equity awards granted by the Company. Although non-cash compensation is a recurring charge to the Company’s operations, management has excluded it because it relies on valuations based on future events, such as the market price of the Company’s common stock, that are difficult to predict and are affected by market factors that are largely not within the control of the Company. Thus, management believes that excluding non-cash compensation facilitates comparisons of the Company’s operational performance in different periods, as well as with similarly determined non-GAAP financial measures of comparable companies.

 

Separation related expenses. The Company excludes separation related expenses from non-GAAP adjusted EBITDA primarily because such expenses are not reflective of the Company’s ongoing operating results and are not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.

 

 

 

 

Litigation reserve. The Company excludes litigation reserve from non-GAAP adjusted EBITDA primarily because such reserve is not reflective of the Company’s ongoing operating results and is not used by management to assess the core profitability of the Company’s business operations. The Company further believes that excluding this item from its non-GAAP results is useful to investors in that it allows for period-over-period comparability.

 

Non-GAAP adjusted EBITDA is reconciled to net loss, the most directly comparable GAAP measure, in the press release.

 

Non-GAAP financial measures are not in accordance with, or an alternative for, GAAP measures and may be different from non-GAAP financial measures used by other companies. In addition, non-GAAP financial measures are not based on any comprehensive or standard set of accounting rules or principles. Accordingly, the calculation of the Company’s non-GAAP financial measures may differ from the definitions of other companies using the same or similar names, limiting, to some extent, the usefulness of such measures for comparison purposes. Non-GAAP financial measures have limitations in that they do not reflect all of the amounts associated with the Company’s financial results as determined in accordance with GAAP. Non-GAAP financial measures should only be used to evaluate the Company’s financial results in conjunction with the corresponding GAAP measures. Accordingly, the Company qualifies its use of non-GAAP financial information in a statement when non-GAAP financial information is presented.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press Release of Xtant Medical Holdings, Inc. dated August 4, 2022 entitled “Xtant Medical Announces Second Quarter Financial Results” (furnished herewith)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  XTANT MEDICAL HOLDINGS, INC.
   
  By: /s/ Scott Neils
    Scott Neils
    Chief Financial Officer

 

Date: August 4, 2022

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Xtant Medical Announces Second Quarter 2022 Financial Results

 

BELGRADE, MT, August 4, 2022 – Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the second quarter ended June 30, 2022.

 

“We are pleased to have achieved our highest revenue quarter since the start of the pandemic. Our second quarter revenue increased 2% over the same prior year period, including 8% year-over-year growth in our biologics business, which was fueled by strong demand for our new biologics products and expansion of our distributor network,” said Sean Browne, President and CEO of Xtant Medical. “On the strength of our four key growth pillars, our strategic initiatives are gaining traction, giving us greater confidence regarding our future prospects. Despite the impact on our business from the broader supply chain and macroeconomic challenges, our team continues to execute in bringing life changing orthobiologics and spinal implant systems to patients in need.”

 

Second Quarter 2022 Financial Results

 

Second quarter 2022 revenue was $15.3 million, compared to $14.9 million for the same quarter in 2021. The increase in revenue is attributed primarily to introductions of new products and increased private label and original equipment manufacturer (OEM) sales.

 

Gross margin for the second quarter of 2022 was 54.8%, compared to 63.5% for the same period in 2021. The decrease is primarily attributable higher product costs and increased charges for excess and obsolete inventory.

 

Operating expenses for the second quarter of 2022 totaled $9.7 million compared to $10.0 million for the second quarter of 2021. The decrease was primarily due to legal settlement expenses in 2021, partially offset by higher sales and marketing expenses in 2022.

 

Second quarter 2022 net loss totaled $1.7 million, or $0.02 per share, compared to the second quarter 2021 net loss of $0.7 million, or $0.01 per share.

 

Non-GAAP Adjusted EBITDA for the second quarter of 2022 totaled a loss of $0.4 million, compared to Non-GAAP Adjusted EBITDA of $0.9 million for the prior-year period. The Company defines Adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income taxes, and as further adjusted to add back in or exclude, as applicable, non-cash compensation, separation related expenses, and litigation settlement reserves. A calculation and reconciliation of Adjusted EBITDA to net loss can be found in the attached financial tables.

 

Conference Call

 

Xtant Medical will host a webcast and conference call to discuss the second quarter 2022 financial results on Thursday, August 4, 2022 at 9:00 AM ET. To access the webcast, Click Here. To access the conference call, dial 877-407-6184 within the U.S. or 201-389-0877 outside the U.S. A replay of the call will be available at www.xtantmedical.com under “Investor Info.”

 

 
 

 

About Xtant Medical Holdings, Inc.

 

Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

 

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

 

Non-GAAP Financial Measures

 

To supplement the Company’s consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

 

Cautionary Statement Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “intends,” ‘‘expects,’’ ‘‘anticipates,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “potential,” “going forward,” similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the future success of the Company’s four key growth pillars and strategic initiatives and its future prospects. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; the ability to increase or maintain revenue; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory if revenues continue to decrease; the ability to remain competitive; the ability to innovate, develop and introduce new products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company’s dependence on key independent agents for a significant portion of its revenue; the effect of the COVID-19 pandemic and hospital staffing shortages on the Company’s business, operating results and financial condition, especially when they affect key markets; the Company’s ability to implement successfully its future growth initiatives and risks associated therewith; the effect of product sales mix changes on the Company’s financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to obtain additional financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (SEC) on March 8, 2022 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 anticipated to be filed with the SEC. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

 

Investor Relations Contact

 

David Carey

Lazar FINN

Ph: 212-867-1762

Email: david.carey@finnpartners.com

 

 
 

 

XTANT MEDICAL HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except number of shares and par value)

 

   As of
June 30, 2022		   As of
December 31, 2021		 
ASSETS          
Current Assets:          
Cash and cash equivalents  $16,495   $18,243 
Restricted Cash   352    144 
Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $510 and $552, respectively   8,600    7,154 
Inventories   16,461    17,945 
Prepaid and other current assets   424    844 
Total current assets   42,332    44,330 
           
Property and equipment, net   5,529    5,212 
Right-of -use asset, net   1,033    1,258 
Goodwill   3,205    3,205 
Intangible assets, net   372    400 
Other assets   242    287 
Total Assets  $52,713   $54,692 
           
LIABILITIES & STOCKHOLDERS' EQUITY          
Current Liabilities:          
Accounts payable  $3,043   $2,615 
Accrued liabilities   4,538    4,349 
Current portion of lease liability   479    462 
Current portion of finance lease obiligations   60    31 
Line of credit   3,736    3,620 
Total current liabilities   11,856    11,077 
Long-term Liabilities:          
Lease liability, less current portion   598    842 
Finance lease obligations, less current portion   213    103 
Long-term debt, plus premium and less issuance costs   11,902    11,787 
Total Liabilities   24,569    23,809 
           
Stockholders' Equity          
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding   -    - 
Common stock, $0.000001 par value; 300,000,000 shares authorized; 87,313,701 shares issued and outstanding as of June 30, 2022 and 87,068,980 shares issued and outstanding as of December 31, 2021   -    - 
Additional paid-in capital   267,252    266,068 
Accumulated deficit   (239,108)   (235,185)
Total Stockholders’ Equity   28,144    30,883 
           
Total Liabilities & Stockholders’ Equity  $52,713   $54,692 

 

 
 

 

XTANT MEDICAL HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited, in thousands, except number of shares and per share amounts)

 

   Three Months Ended
June 30,		   Six Months Ended
June 30,		 
   2022   2021   2022   2021 
Revenue                    
Orthopedic product sales  $15,277   $14,942   $28,227   $27,451 
Other revenue   -    33    9    66 
Total Revenue   15,277    14,975    28,236    27,517 
                     
Cost of sales   6,903    5,460    12,302    9,911 
Gross Profit   8,374    9,515    15,934    17,606 
                     
Gross Profit %   54.8%   63.5%   56.4%   64.0%
                     
Operating Expenses                    
General and administrative   3,797    4,173    7,766    7,200 
Sales and marketing   5,636    5,590    10,845    10,445 
Research and development   241    243    454    458 
Total Operating Expenses   9,674    10,006    19,065    18,103 
                     
Loss from Operations   (1,300)   (491)   (3,131)   (497)
                     
Other Expense                    
Interest expense   (397)   (199)   (757)   (201)
Total Other Expense   (397)   (199)   (757)   (201)
Net Loss Before Provision for Income Taxes   (1,697)   (690)   (3,888)   (698)
                     
Provision for Income Taxes   (13)   (43)   (35)   (64)
Net Loss  $(1,710)  $(733)  $(3,923)  $(762)
                     
Net Loss Per Share:                    
Basic  $(0.02)  $(0.01)  $(0.04)  $(0.01)
Dilutive  $(0.02)  $(0.01)  $(0.04)  $(0.01)
                     
Shares used in the computation:                    
Basic   87,313,701    86,707,286    87,252,521    83,993,159 
Dilutive   87,313,701    86,707,286    87,252,521    83,993,159 

 

 
 

 

XTANT MEDICAL HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited, in thousands)

 

   Six Months Ended 
   June 30, 
   2022   2021 
Operating activities:          
Net loss  $(3,923)  $(762)
Adjustments to reconcile net loss to net cash provided by operating activities:          
Depreciation and amortization   599    731 
Gain on disposal of fixed assets   (84)   (108)
Non-cash interest   116    16 
Non-cash rent expense   (1)   5 
Stock-based compensation   1,184    921 
Provision for reserve on accounts receivable   143    (143)
Provision for excess and obsolete inventory   825    211 
           
Changes in operating assets and liabilities:          
Accounts receivable   (1,589)   38 
Inventories   659    104 
Prepaid and other assets   465    (29)
Accounts payable   428    (308)
Accrued liabilities   189    266 
Net cash (used in) provided by operating activities   (989)   942 
Investing activities:          
Purchases of property and equipment   (810)   (1,079)
Proceeds from sale of fixed assets   165    125 
Net cash used in investing activities   (645)   (954)
Financing activities:          
Payments on financing leases   (22)   (34)
Costs associated with refinancing   -    (32)
Payments on long-term debt   -    (484)
Borrowings on line of credit   26,567    9,331 
Repayments of line of credit   (26,451)   (9,009)
Proceeds from private placement, net of cash issuance costs   -    18,426 
Net cash used in financing activities   94    18,198 
           
Net change in cash and cash equivalents and restricted cash   (1,540)   18,186 
Cash and cash equivalents and restricted cash at beginning of period   18,387    2,341 
Cash and cash equivalents and restricted cash at end of period  $16,847   $20,527 
           
           
Reconciliation of cash and restricted cash reported in the condensed consolidated balance sheets          
Cash and cash equivelants  $16,495   $20,312 
Restricted cash   352    215 
Total cash and restricted cash reported in the condensed consolidated balance sheets  $16,847   $20,527 

 

 
 

 

XTANT MEDICAL HOLDINGS, INC.

CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA

(Unaudited, in thousands)

 

   Three Months Ended June 30,   Six Months Ended June 30, 
   2022   2021   2022   2021 
                 
Net Loss  $(1,710)  $(733)  $(3,923)  $(762)
                     
Depreciation and amortization   317    357    599    731 
Interest expense   397    199    757    201 
Tax expense   13    43    35    64 
Non-GAAP EBITDA   (983)   (134)   (2,532)   234 
                     
Non-GAAP EBITDA/Total revenue   -6.4%   -0.9%   -9.0%   0.9%
                     
NON-GAAP ADJUSTED EBITDA CALCULATION                    
Non-cash compensation   571    465    1,185    921 
Separation-related expenses   -    -    3    - 
Litigation reserve   -    550    -    550 
Non-GAAP Adjusted EBITDA  $(412)  $881   $(1,344)  $1,705 
                     
Non-GAAP Adjusted EBITDA/Total revenue   -2.7%   5.9%   -4.8%   6.2%

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 xtnt-20220804.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 xtnt-20220804_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Entity Information, Former Legal or Registered Name EX-101.PRE 6 xtnt-20220804_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover
Aug. 04, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 04, 2022
Entity File Number 001-34951
Entity Registrant Name XTANT MEDICAL HOLDINGS, INC.
Entity Central Index Key 0001453593
Entity Tax Identification Number 20-5313323
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 664 Cruiser Lane
Entity Address, City or Town Belgrade
Entity Address, State or Province MT
Entity Address, Postal Zip Code 59714
City Area Code (406)
Local Phone Number 388-0480
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.000001 per share
Trading Symbol XTNT
Security Exchange Name NYSEAMER
Entity Emerging Growth Company false
Entity Information, Former Legal or Registered Name Not Applicable
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001453593 2022-08-04 2022-08-04 iso4217:USD shares iso4217:USD shares 0001453593 false 8-K 2022-08-04 XTANT MEDICAL HOLDINGS, INC. DE 001-34951 20-5313323 664 Cruiser Lane Belgrade MT 59714 (406) 388-0480 Not Applicable false false false false Common stock, par value $0.000001 per share XTNT NYSEAMER false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://xtantmedical.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm xtnt-20220804.xsd xtnt-20220804_lab.xml xtnt-20220804_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "xtnt-20220804_lab.xml" ] }, "presentationLink": { "local": [ "xtnt-20220804_pre.xml" ] }, "schema": { "local": [ "xtnt-20220804.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 60, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "XTNT", "nsuri": "http://xtantmedical.com/20220804", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-08-04to2022-08-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://xtantmedical.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-08-04to2022-08-04", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://xtantmedical.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-021233-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-021233-xbrl.zip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�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end